PMID: 6964817Jan 1, 1981Paper

Blast cells in acute myeloblastic leukemia: a model

Blood Cells
E A McCulloch, J E Till

Abstract

A model of the evolution of acute myeloblastic leukemia (AML) as a clonal hemopathy is presented and reviewed in light of the available data on the behavior of leukemic blast-stem cell colonies. The model postulates that determination of a pluripotent stem cell of a leukemic clone occurs abruptly with intermediate stem cell classes being rare. Transformations occurring in committed myelopoietic progenitors are not self-maintaining. Leukemic clones in AML originate by genetic transformation to a lineage independent of myelopoietic differentiation. The biological behavior of AML clones changes with time as a result, in the short term, of environmental changes, and in the long term, of genetic changes. Sensitivity of leukemic blast colonies to adriamycin and Ara-C, although variable from patient to patient, is relatively stable for one clone during a major portion of the course of the disease.

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.